Bentracimab

CHICAGO — Bentracimab, a recombinant human immunoglobulin G1 monoclonal antibody fragment, restored platelet function in patients on ticagrelor undergoing urgent surgery or with major bleeding, according to data from the REVERSE-IT trial.

WASHINGTON — The IV monoclonal antibody bentracimab immediately and significantly reversed the antiplatelet effect of ticagrelor in healthy older adults, with no related serious adverse events, researchers reported.